Synapse - Works

Results (5599)

A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer

Meeting Abstract

Liu, J. F.; Brady, M. F.; Matulonis, U. A.; Miller, A.; Kohn, E. C.; Swisher, E. M.; Tew, W. P.; Cloven, N. G.; Muller, C.; Bender, D.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

Randomized phase III trial of eribulin (E) versus standard weekly paclitaxel (P) as first- or second-line therapy for locally recurrent or metastatic breast cancer (MBC)

Meeting Abstract

Liu, M. C.; Hillman, D. W.; Frith, A. E.; Lyss, A. P.; Weckstein, D. J.; Moreno-Aspitia, A.; Le-Lindqwister, N.; Isaacs, C.; Wender, D. B.; Lewis, D. A.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

Survival outcomes of patients with resectable pancreatic cancer treated with upfront surgery versus neoadjuvant chemotherapy: A retrospective tertiary care center experience

Meeting Abstract

Liu, F.; Mirsky, M.; Wu, S.; Fu, P.; Cao, S.; Shanahan, J.; Kyasaram, R. K.; Jain, P.; Hardacre, J.; Ammori, J. B.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) and renal impairment

Meeting Abstract

Lee, H. C.; Cohen, A. D.; Chari, A.; Hultcrantz, M.; Nooka, A. K.; Callander, N. S.; Suvannasankha, A.; Badros, A.; Libby, E. N.; Trudel, S.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

A phase Ib study to evaluate the oral selective estrogen receptor degrader GDC-9545 alone or combined with palbociclib in metastatic ER-positive HER2-negative breast cancer

Meeting Abstract

Lim, E.; Jhaveri, K. L.; Perez-Fidalgo, J. A.; Bellet, M.; Boni, V.; Garcia, J. M. P.; Estevez, L.; Bardia, A.; Turner, N. C.; Villanueva, R.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

Phase II trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for disease progression after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell renal cell carcinoma (mccRCC)

Meeting Abstract

Lee, C. H.; Shah, A. Y.; Hsieh, J. J.; Rao, A.; Pinto, A.; Bilen, M. A.; Cohn, A. L.; Di Simone, C.; Shaffer, D. R.; Sarrio, R. G.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

Safety and efficacy of pyrotinib in patients with NSCLC and other advanced solid tumors with activating HER2 alterations: A phase I basket trial

Meeting Abstract

Li, B. T.; Li, T.; Johnson, M. L.; Waqar, S. N.; Zhu, V. W.; Ou, S. H. I.; Lin, J. J.; Wang, D.; Shapiro, G.; Wang, J. S. Z.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

Primary efficacy and biomarker analyses from the VISION study of tepotinib in patients (pts) with non-small cell lung cancer (NSCLC) with METex14 skipping

Meeting Abstract

Le, X.; Felip, E.; Veillon, R.; Sakai, H.; Cortot, A. B.; Garassino, M. C.; Mazieres, J.; Ramirez, S. V.; Senellart, H.; Van Meerbeeck, J.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

Quality-adjusted time without symptoms or toxicity (Q-TWiST) of lenvatinib plus everolimus versus everolimus monotherapy in patients with advanced renal cell carcinoma (RCC)

Meeting Abstract

Lee, C. H.; Wan, Y.; Smith, A. D.; Xie, R.; Motzer, R. J.
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

Changes in cancer mortality rates after the adoption of the Affordable Care Act

Meeting Abstract

Lee, A.; Shah, K.; Chino, J. P.; Chino, F.
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save